Sirtex to Participate in the 2007 American Society of Clinical Oncology Annual Meeting.New Data Regarding Repeat Treatments of SIR-Spheres[R] Microspheres in Patients with Advanced Liver Tumors to Be Included at Annual Meeting WILMINGTON, Mass. -- Sirtex, a leading developer of targeted and innovative cancer therapies, will exhibit its SIR-Spheres microspheres technology at the 43rd American Society of Clinical Oncology American Society of Clinical Oncology, or ASCO, is an organization that represents all clinical oncologists. Every year, ASCO holds a large symposium where physicians and researchers meet to convey and discuss research and ideas. (ASCO ASCO American Society of Clinical Oncology ASCO Association of Schools and Colleges of Optometry (since 1941; Rockville, Maryland) ASCO Australian Standard Classification of Occupations ASCO Automatic Switch Company ) Annual Meeting. The meeting, to be held June 1-5 at the McCormick Place in Chicago, Ill., is considered the premier educational and scientific event in the oncology community. Sirtex manufactures SIR-Spheres microspheres, the only FDA-approved microsphere Not to be confused with Glass microphere. This article largely refers to micropheres or protein protocells as small spherical units postulated by some scientists as a key stage in the origin of life. therapy for advanced colorectal cancer colorectal cancer Malignant tumour of the large intestine (colon) or rectum. Risk factors include age (after age 50), family history of colorectal cancer, chronic inflammatory bowel diseases, benign polyps, physical inactivity, and a diet high in fat. that has spread to the liver.1 In addition to the exhibition, new data regarding repeat treatments of SIR-Spheres microspheres will be included in the program. The paper, authored by Andrew Kennedy, M.D., F.A.C.R.O., co-medical director of Wake Radiology Oncology in Cary, N.C., examined safety and patient selection regarding repeat microsphere radioembolization for hepatic malignancies. As patients live longer with hepatic tumors, a growing number of them require retreatment. According to Kennedy, with proper patient selection, repeat radiation to the liver with SIR-Spheres microspheres is safe and no dosing adjustments are needed. "Sirtex is proud to support ASCO and its mission to improve cancer care and prevention and to ensure that all cancer patients receive care of the highest quality," says Nat Geissel, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Sirtex Medical Inc. "We believe it is imperative that Sirtex continues to participate in meetings such as this to allow physicians the opportunity to learn about the latest advances and research regarding SIR-Spheres microspheres. We are able to speak directly with physicians and provide information that will ultimately help improve the level of care we are able to offer patients with advanced liver disease." Sirtex's SIR-Spheres microspheres are radioactive polymer spheres that emit beta radiation. Physicians insert a catheter through the groin into the hepatic artery and deliver millions of SIR-Spheres microspheres directly to the tumor site. According to a paper in the International Journal of Radiation Oncology Biology Physics, the use of SIR-Spheres microspheres in patient responders resulted in a median survival rate of 10.5 months from treatment. 1Sirtex Medical Inc.'s SIR-Spheres[R] microspheres are indicated for the treatment of non-resectable metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. colorectal cancer in combination with intra-arterial FUDR FUDR, FUdR floxuridine. FUDR see floxuridine. chemotherapy. Information regarding other disease states or agents in combination with this device that is presented in peer-reviewed literature is different from the approved USA labeling for SIR-Spheres. About Selective Internal Radiation Therapy internal radiation therapy Brachytherapy, see there (SIRT) using SIR-Spheres microspheres Selective Internal Radiation Therapy (SIRT) is a novel treatment for inoperable inoperable /in·op·er·a·ble/ (in-op´er-ah-b'l) not susceptible to treatment by surgery. in·op·er·a·ble adj. Unsuitable for a surgical procedure. liver cancer that delivers high doses of radiation directly to the site of tumors. In a minimally-invasive treatment, millions of radioactive SIR-Spheres microspheres are infused via a catheter into the liver where they selectively target liver tumors with a dose of internal radiation up to 40 times higher than conventional radiotherapy, while sparing healthy tissue. Clinical trials have confirmed that liver cancer patients treated with SIR-Spheres microspheres have response rates higher than with other forms of treatment, resulting in increased life expectancy, greater periods without tumor activity, and improved quality of life. SIRT has been found to shrink liver tumors more than chemotherapy alone. SIRT using SIR-Spheres microspheres is approved for use in Australia, New Zealand, the United States of America UNITED STATES OF AMERICA. The name of this country. The United States, now thirty-one in number, are Alabama, Arkansas, Connecticut, Delaware, Florida, Georgia, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Mississippi, Missouri, New Hampshire, (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval), European Union (CE Mark), Hong Kong, Malaysia, Singapore, Thailand, Israel, and India. SIRT is available in 140 treatment centers around the world, and more than 6500 patients have been treated to date. Approximately 90 physicians in the United States use Sirtex's SIR-Spheres microspheres in more than 86 medical centers. For more information, visit www.sirtex.com. [R] SIR-Spheres is a Registered Trademark of Sirtex SIR-Spheres Pty Ltd |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion